MedTrace Logo

Study to Investigate the Safety and Efficacy of GC3107 (BCG Vaccine) in Healthy Adults

NCT03363178 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-12-18

No results posted yet for this study

Summary

Healthy adults will be once administered GC3107(BCG Vaccine) Intradermally.

Conditions

Interventions

BIOLOGICAL

GC3107

BCG Vaccine, 0.1mL

Sponsors & Collaborators

  • Green Cross Corporation

    lead INDUSTRY

Principal Investigators

  • Woo Joo Kim, M.D, Ph.D · Korea University Guro Hospital

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-12-14
Primary Completion
2018-03-31
Completion
2018-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03363178 on ClinicalTrials.gov